Related Experiment Video

Updated: Jan 4, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure

Deepak L Bhatt1, Subodh Verma2, Eugene Braunwald1

  • 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Cell Metabolism
|November 7, 2019
PubMed

Insights

The SGLT2 inhibitor dapagliflozin significantly reduced mortality and heart failure events in patients with reduced ejection fraction. These benefits were observed in both diabetic and non-diabetic individuals, suggesting a new treatment approach for heart failure.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality worldwide.
  • Current treatments for HFrEF have limitations, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of the SGLT2 inhibitor dapagliflozin in patients with HFrEF.
  • To determine if the benefits of dapagliflozin extend to patients regardless of their diabetes status.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial was conducted.
  • Patients with symptomatic HFrEF were enrolled and received either dapagliflozin or a placebo.
  • Primary endpoints included cardiovascular death and worsening heart failure events.

Main Results:

  • Dapagliflozin significantly reduced the composite endpoint of cardiovascular death and worsening heart failure compared to placebo.
  • The observed benefits of dapagliflozin were consistent across subgroups, including patients with and without type 2 diabetes.
  • No significant safety concerns were identified with dapagliflozin treatment.

Conclusions:

  • Dapagliflozin represents a novel therapeutic option for patients with HFrEF, irrespective of diabetes status.
  • These findings establish a new paradigm in the management of heart failure, expanding treatment possibilities beyond traditional therapies.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
186
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
759
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
220
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
863
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
274
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
415